{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.8","upperLimit":"51.9","value":"46.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"}],"units":"Participants"}],"description":"The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. OS at Month 12 was calculated using product-limit (Kaplan-Meier) method for censored data. Participants were censored at the date of their last assessment. Per protocol, only data generated during the initial course of treatment contributed to the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment during the initial course of treatment","reportingStatus":"POSTED","timeFrame":"Month 12","title":"Overall Survival Rate (OS Rate) at Month 12 in All Participants","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}